Related Experiment Video
Updated: Aug 21, 2026
Combined In vivo Optical and µCT Imaging to Monitor Infection, Inflammation, and Bone Anatomy in an Orthopaedic Implant Infection in Mice
Published on: October 16, 2014
In vitro experimental study of MC-PMMA containing vancomycin for the prevention of infection in open bone defects
Haitao Liu1, Yu Bo1, Pengcheng Gao1
1Department of Traumatic Orthopedics, General Hospital of Ningxia Medical University, Yinchaun, Ningxia, China.
Abstract:
In this study, vancomycin, bone cement (PMMA) and mineralized collagen (MC) were mixed in order to obtain a new composite drug-carrying biomaterial, which has good results in both drug slow release, good biocompatibility, and good growth of osteoblasts, osteoclasts, and mesenchymal stem cells on the surface of the biomaterial, which provides a new therapeutic idea for the clinical treatment of bone defect infections. In this study, the drug retardation system of vancomycin and mineralized collagen composite bone cement-carrying biomaterials was prepared in proportion to the drug retardation system, and the experimental studies were carried out using electron microscope scanning, HPLC drug retardation analysis, in vitro antimicrobials, and co-cultivation of osteoclasts, osteoblasts, and mesenchymal stem cells. We found that the composite drug-carrying material of vancomycin, bone cement and mineralized collagen had good slow-release effect and antimicrobial properties, and the addition of vancomycin and bone cement to mineralized collagen material had even better drug-release efficiency than that of bone cement plus vancomycin alone. In vitro antimicrobial showed that the composite material has excellent antimicrobial effect against Staphylococcus aureus. Co-culture of osteoblasts, osteoclasts and mesenchymal stem cells with the material showed that the cells were morphologically complete on the surface of the composites with good growth status. Vancomycin, bone cement and mineralized collagen composite drug-carrying biomaterials have excellent slow-release effect and antimicrobial properties with good biocompatibility, which is a new therapeutic idea for the future clinical treatment of bone defect infections.
Insights
A novel composite biomaterial combining vancomycin, bone cement (PMMA), and mineralized collagen (MC) demonstrates excellent slow drug release and antimicrobial properties. This vancomycin-PMMA-MC composite shows promise for treating bone defect infections with good biocompatibility and cell growth.
Area of Science:
- Biomaterials Science
- Drug Delivery Systems
- Orthopedic Surgery
Background:
- Bone defect infections pose significant clinical challenges, often requiring effective antimicrobial strategies and materials that support bone regeneration.
- Current treatments may face limitations in drug elution kinetics, biocompatibility, and host cell integration.
- Developing advanced drug-carrying biomaterials is crucial for improving therapeutic outcomes in orthopedic infections.
Purpose of the Study:
- To develop and characterize a novel composite biomaterial integrating vancomycin, bone cement (PMMA), and mineralized collagen (MC) for enhanced drug delivery and bone defect treatment.
- To evaluate the drug release profile, antimicrobial efficacy, and biocompatibility of the vancomycin-PMMA-MC composite.
- To assess the material's interaction with critical bone cells, including osteoblasts, osteoclasts, and mesenchymal stem cells.
Main Methods:
- Preparation of a composite drug-carrying biomaterial by mixing vancomycin, PMMA, and MC in specific proportions.
- Characterization using scanning electron microscopy (SEM) and High-Performance Liquid Chromatography (HPLC) for drug release analysis.
- In vitro antimicrobial assays against Staphylococcus aureus.
- Co-culture studies with osteoblasts, osteoclasts, and mesenchymal stem cells to evaluate biocompatibility and cell growth.
Main Results:
- The vancomycin-PMMA-MC composite exhibited a favorable slow-release profile for vancomycin.
- The composite demonstrated significant in vitro antimicrobial activity against Staphylococcus aureus.
- Co-culture experiments revealed excellent biocompatibility, with cells maintaining complete morphology and showing good growth on the material surface.
- The composite material showed enhanced drug-release efficiency compared to vancomycin and PMMA alone.
Conclusions:
- The developed vancomycin-PMMA-MC composite biomaterial offers a promising therapeutic strategy for bone defect infections.
- Its excellent slow-release properties, potent antimicrobial effects, and superior biocompatibility make it a valuable candidate for clinical applications.
- This novel material supports osteoblast, osteoclast, and mesenchymal stem cell growth, facilitating potential bone regeneration alongside infection control.
